All Research Papers Published In Clinical Genitourinary Cancer

Research Article
1
10.1016/j.clgc.2024.102109

Thermal Ablation for Small Renal Masses: Identifying Anthropometric Factors for Predicting Perioperative and Oncological Outcomes

Apr 30, 2024
Clinical Genitourinary Cancer
Gennaro Musi + 15 more +15

Research Article
7
10.1016/j.clgc.2024.102104

Racial and Ethnic Disparities in Survival Outcomes of Metastatic Renal Cell Carcinoma Patients Receiving Immunotherapy

Apr 25, 2024
Clinical Genitourinary Cancer
Amol Gupta + 1 more +1

Research Article
10.1016/j.clgc.2024.102103

Hormonal Therapy and Radiation Therapy in Prostate Cancer: 5-Year Outcomes From a Trial Evaluating Combined Androgen Blockade With 5-Alpha Reductase Inhibitors as an Alternative to Gonadotropin Releasing Hormone Agonists

Apr 24, 2024
Clinical Genitourinary Cancer
Greeshma Rajeev-Kumar + 5 more +5

Research Article
9
10.1016/j.clgc.2024.102105

Unmarried Status Effect on Stage at Presentation and Treatment Patterns in Non-Metastatic Upper Tract Urothelial Carcinoma Patients

Apr 24, 2024
Clinical Genitourinary Cancer
Simone Morra + 23 more +23

Research Article
6
10.1016/j.clgc.2024.102090

Racial Differences in Cutaneous Events Among Patients Receiving Enfortumab Vedotin

Apr 07, 2024
Clinical Genitourinary Cancer
Evangelia Vlachou + 5 more +5

Research Article
11
10.1016/j.clgc.2024.102085

Disitamab Vedotin Alone or in Combination With Immune Checkpoint Inhibitors in Bladder-Sparing Treatment of Muscle-Invasive Bladder Cancer: A Real-World Study

Mar 26, 2024
Clinical Genitourinary Cancer
Anbang Wang + 6 more +6

Research Article
12
10.1016/j.clgc.2024.102066

Cardiovascular Toxicity Associated With Androgen Receptor Axis-Targeted Agents in Patients With Prostate Cancer: A Meta-analysis of Randomized Controlled Trials

Mar 08, 2024
Clinical Genitourinary Cancer
Susu Zhou + 5 more +5

Research Article
3
10.1016/j.clgc.2024.02.004

Clinical Profile and Outcomes of Carcinoma Penis Patients Receiving Systemic Therapy at an Indian tertiary care Center: A Retrospective Observational Study

Feb 07, 2024
Clinical Genitourinary Cancer
Vanita Noronha + 13 more +13

Research Article
2
10.1016/j.clgc.2024.01.019

Treatment Patterns and Survival Outcomes Before and After Access to Immune Checkpoint Inhibitors for Patients With Metastatic Urothelial Carcinoma: A Single-Center Retrospective Study From 2004 to 2021

Feb 01, 2024
Clinical Genitourinary Cancer
Jose C Tapia + 8 more +8

Research Article
11
10.1016/j.clgc.2024.01.008

The Prognostic Value of Tumor Infiltrating Lymphocytes After Radical Cystectomy for Bladder Cancer: A Systematic Review and Meta-Analysis

Jan 17, 2024
Clinical genitourinary cancer
Tatsushi Kawada + 12 more +12

BackgroundWe aimed to assess the prognostic value of tumor infiltrating lymphocytes (TILs) in patients with bladder cancer (BC) after radical cystectomy (RC). Materials and MethodsWe searched Pubmed, Web of Science and Scopus in April 2022 to identify studies assessing the prognostic value of TILs, including a subset of lymphocytes (eg, CD3, CD8, FOXP3), after RC. The endpoints were overall survival and recurrent free survival. Subgroup analyses were performed based on the evaluation method for TILs (ie, CD3, CD8, FOXP3, HE staining). ResultsOverall, 9 studies comprising 1413 patients were included in this meta-analysis. The meta-analysis revealed that elevated expressions of TILs were significantly associated with favorable OS (pooled hazard ratio [HR]: 0.65, 95% confidence interval [CI]: 0.51-0.83) and RFS (pooled HR: 0.48, 95% CI: 0.35-0.64). In subgroup analyses, high CD8+ TILs were also associated with favorable OS (HR: 0.51, 95% CI: 0.33-0.80) and RFS (pooled HR: 0.53, 95% CI: 0.36-0.76). Among 3 studies comprising 146 patients, high intratumoral TILs were significantly associated with favorable OS (pooled HR: 0.34, 95% CI: 0.19-0.60). ConclusionTILs are useful prognostic markers in patients treated with RC for BC. Although the prognostic value of TILs is varied, depending on the subset and infiltration site, CD8+ TILs and intratumoral TILs are associated with oncologic outcomes. Further studies are warranted to explicate the predictive value of TILs on the response to perioperative systemic therapy to help clinical decision-making in patients with BC.